If You Invested in Anixa Biosciences Inc (ANIX)

Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. According to the company’s public statements, Anixa concentrates on two main areas: an ovarian cancer immunotherapy program and a portfolio of cancer vaccines, with particular emphasis on breast and ovarian cancer. The company describes itself as working with world-renowned research institutions to advance these programs from early research through clinical development.

Core focus and therapeutic portfolio

Anixa states that its therapeutic portfolio includes an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center. This program uses a novel type of CAR-T cell technology referred to as chimeric endocrine receptor-T cell (CER-T) therapy. In this approach, the natural ligand of the follicle stimulating hormone receptor (FSHR), follicle stimulating hormone (FSH), binds to FSHR on tumor cells rather than relying on an antibody fragment. The company notes that this technology is being evaluated in a first-in-human trial for women with recurrent ovarian cancer who have progressed after at least two prior therapies.

In addition to cell therapy, Anixa highlights a vaccine portfolio developed in collaboration with Cleveland Clinic. These vaccines are intended to treat and prevent certain cancers, including breast and ovarian cancer, as well as other intractable cancers such as high-incidence malignancies in lung, colon, and prostate. The company describes these vaccine technologies as focusing on immunizing against so-called “retired” proteins that are generally absent from normal adult tissues but have been found to be expressed in certain forms of cancer.

Breast cancer vaccine program

A central program for Anixa is its investigational breast cancer vaccine, developed with Cleveland Clinic. Public disclosures explain that this vaccine targets α-lactalbumin, a lactation-associated protein that is typically expressed only in breast tissue during lactation but re-emerges in many forms of breast cancer. By establishing an immune response against α-lactalbumin-expressing cells, the vaccine is designed to direct cytotoxic T cells toward tumor cells that express this antigen.

The company has reported that a Phase 1 clinical trial of this vaccine, conducted at Cleveland Clinic and funded by a grant from the U.S. Department of Defense, evaluated safety and immunogenicity in multiple cohorts. According to Anixa and Cleveland Clinic, the trial met its major primary endpoints, the vaccine was reported as safe and well tolerated at the maximum tolerated dose, and protocol-defined immune responses were observed in a majority of participants. The company has also indicated that it is assuming sponsorship of the related Investigational New Drug (IND) application from Cleveland Clinic and plans to advance the program into a Phase 2 clinical trial, utilizing multiple clinical sites.

Anixa has also announced intellectual property developments around this program, including U.S. and Chinese patents covering key aspects of the breast cancer vaccine technology. The company states that these patents protect methods of inducing an immune response to α-lactalbumin and extend foundational patent protection for the breast cancer vaccine program into the 2040s in multiple jurisdictions.

Ovarian cancer CER-T (CAR-T) program

On the cell therapy side, Anixa describes its ovarian cancer program as based on FSHR-mediated CAR-T technology, also referred to as CER-T. The therapy targets FSHR, which the company notes is expressed on normal ovarian cells, tumor vasculature, and certain cancer cells. The target-binding domain is derived from the natural hormone ligand, FSH, rather than an antibody fragment, which is why the company characterizes it as a chimeric endocrine receptor approach.

Anixa has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved the non-proprietary name “liraltagene autoleucel” (lira-cel) for this CAR-T therapy. The therapy is being evaluated in a first-in-human clinical trial enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies. The study is designed to evaluate safety, identify a maximum tolerated dose, and monitor clinical activity. The underlying technology has been described as exclusively licensed to Anixa from The Wistar Institute.

Collaboration-driven business model

Anixa repeatedly emphasizes a collaboration-based business model. The company states that it partners with institutions such as Cleveland Clinic, Moffitt Cancer Center, and The Wistar Institute for discovery, development, and clinical evaluation of its programs. According to Anixa, the breast and ovarian cancer vaccines were developed at Cleveland Clinic and are exclusively licensed to the company, with Cleveland Clinic entitled to royalties and other commercialization revenues related to these technologies.

The company also notes that Moffitt Cancer Center is a key partner in its ovarian cancer CER-T program and characterizes Moffitt as a center that has pioneered next-generation cell therapies, including CAR-T and tumor infiltrating lymphocytes (TILs). Anixa describes its model as enabling it to continually examine emerging technologies in complementary fields for potential development and commercialization.

Cancer vaccine strategy and “retired” proteins

Across its vaccine programs, Anixa highlights a strategy of targeting “retired” proteins. In the company’s description, these are proteins that are generally expressed in specific physiological states (such as lactation) but are otherwise absent from normal adult tissues, while being aberrantly expressed in certain cancers. By focusing on such proteins, Anixa aims to prime the immune system to recognize and eliminate pre-malignant and malignant cells expressing these targets, while limiting effects on normal tissues.

In the case of the breast cancer vaccine, α-lactalbumin is presented as a prototypical retired protein: typically present in normal breast tissue only during lactation, but also expressed in certain breast cancers. Anixa has stated that its investigational vaccine aims to stimulate immune responses against α-lactalbumin-expressing cells, with the goal of providing immune protection against tumors that express this antigen.

Intellectual property and regulatory milestones

Anixa has publicly reported several intellectual property milestones for its programs. These include a U.S. patent covering methods of inducing an immune response to α-lactalbumin, as well as a Chinese patent covering key aspects of the breast cancer vaccine technology. The company indicates that these patents contribute to a global patent estate intended to support future development and potential commercialization strategies in markets with high breast cancer incidence.

On the regulatory side, Anixa has highlighted the assignment of the WHO International Nonproprietary Name for its ovarian cancer CER-T therapy, liraltagene autoleucel, as a step toward global recognition of the therapy’s active ingredient. The company also reports progress in the regulatory pathway for its breast cancer vaccine, including completion of a Phase 1 trial, presentation of final data at a major scientific meeting, and steps to transfer IND sponsorship from Cleveland Clinic to Anixa.

Company status and exchange listing

In its news releases, Anixa identifies itself as “Anixa Biosciences, Inc. (NASDAQ: ANIX)”, indicating that its common stock trades on the NASDAQ exchange under the ticker symbol ANIX. The company describes itself as a clinical-stage biotechnology company, reflecting that its key programs are in human clinical trials rather than commercial stages. The available information does not indicate any delisting, merger, or bankruptcy events; instead, it focuses on ongoing clinical, regulatory, and intellectual property developments.

Segment perspective and legacy operations

Additional descriptive information notes that Anixa’s operations have been organized into segments such as Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional vaccines targeting cancers including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment centers on liraltagene autoleucel, the ovarian cancer immunotherapy using CER-T technology. The Other segment has been described as consisting of legacy operations, including limited patent licensing activities.

Overall, Anixa Biosciences presents itself as a company focused on developing immunotherapies and vaccines for oncology indications, with a particular emphasis on breast and ovarian cancer, and on leveraging collaborations with major research and cancer centers to advance its programs.